Fermentalg's 2025 Financial Results: Sales Surge and Strengthened Financials

Fermentalg, a specialist in BioSolutions from aquatic microorganisms, reported a record 2025 turnover of €13.4 million, up 17% from 2024. The growth was driven by a diversification into new market segments like infant nutrition and aquaculture, which now comprise 43% of sales, up from 5% the previous year.

Despite a stable operating profit at -€9.5 million, the company improved its net profit to -€9.4 million, aided by managing operating expenses and its partnership with Huvepharma. A post-closing €4 million loan from Huvepharma bolstered its cash reserve to €6.6 million at year-end, supporting accelerated growth initiatives.

Fermentalg remains optimistic about the future, with the launch of new product lines like the ΩRIGINS™ EPA/DHA range and Galdieria Blue, and targets €20 million in revenue by 2026.